Cullinan Therapeutics, Inc.
CGEM · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $350 | $444 | $446 | $714 |
| - Cash | $103 | $73 | $77 | $83 |
| + Debt | $1 | $2 | $2 | $2 |
| Enterprise Value | $248 | $373 | $371 | $633 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$51 | -$76 | -$55 | -$55 |
| % Margin | – | – | – | – |
| Net Income | -$51 | -$70 | -$49 | -$48 |
| % Margin | – | – | – | – |
| EPS Diluted | 0 | -1.19 | -0.82 | -0.81 |
| % Growth | 100% | -45.1% | -1.2% | – |
| Operating Cash Flow | -$37 | -$58 | -$43 | -$37 |
| Capital Expenditures | $37 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$58 | -$43 | -$37 |